title: Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.
abstract: High-dose bolus interleukin-2 (IL-2) was granted Food and Drug Administration approval for the treatment of metastatic renal cell carcinoma based on its ability to produce durable responses in a small number of patients. Results from randomized phase III trials suggest that regimens involving lower doses of IL-2 alone or in combination with interferon produce fewer tumor regressions of decreased overall quality. Because of the toxicity and limited efficacy of this treatment, recent studies have focused on identifying predictors of response (or resistance) to IL-2 therapy. This year, investigators will launch a clinical trial designed to prospectively determine whether patients who are more likely to respond to high-dose IL-2 can be identified before therapy is initiated.
authors.affiliation: Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. dmcdermo@bidmc.harvard.edu
authors.forename: David F
authors.initials: DF
authors.lastname: McDermott
authors.forename: Meredith M
authors.initials: MM
authors.lastname: Regan
authors.forename: Michael B
authors.initials: MB
authors.lastname: Atkins
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000276:immunology / Q000556:secondary; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D007376:Interleukin-2